Walter E. Washington Convention Center
Washington, D.C.
May 16-19, 2022

VGXI, Inc.  

The Woodlands,  TX 
United States
http://www.vgxii.com
  • Booth: 319


We look forward to meeting with you at ASGCT 2021!

VGXI, Inc. is a leading contract manufacturer of DNA-based pharmaceuticals with over 20 years of experience providing exceptional quality GMP products for clients worldwide. Applications include DNA vaccines, immunotherapies, cell and gene therapy, gene editing, and mRNA production.

The company's skilled team has an outstanding track record of success in manufacturing challenging plasmid products under GMP conditions with exceptional yield, quality, and prompt delivery. Low-shear, highly efficient AIRMIX® lysis technology paired with VGXI's optimized purification process provides highly supercoiled plasmid material across production scales including for commercial indications.

A range of production services are available to meet each client's needs:

  • High purity plasmid DNA preparations for pre-clinical research
  • Highly Documented (HD) plasmid DNA manufacturing for use in GMP viral vector production or pharmacology / toxicology studies
  • GMP plasmid DNA manufacturing for clinical through commercial supply
  • Pre-clinical to GMP production of RNA including mRNA and lncRNA


 Videos

Introduction to VGXI

 Press Releases

  • VGXI New Manufacturing Facility Achieves Construction Milestones

    Specialized GMP contract manufacturer VGXI, Inc. announced multiple construction milestones have been reached for its new headquarters and expanded manufacturing facility in Conroe, TX.

    The Woodlands, TX – VGXI, Inc., an industry-leading contract developer and manufacturer (CDMO) for nucleic acid biopharmaceuticals including DNA vaccines and gene therapies, announced that its new headquarters and manufacturing facility located at Deison Technology Park in Conroe, TX is now dried-in with multiple stages of equipment arriving for installation. Only 5 months since the final steel beam was set in place for the building in April, 2021, the dry-in date marks a significant milestone for the 120,000 SQ FT building, allowing interior progress to speed forward regardless of weather conditions. Now that the entire facility exterior is complete, major mechanical equipment including air handlers, process chillers, and the sterile water filtration system components are arriving and being installed. In addition, full site backup generation will be complete this month, enabling uninterrupted power to the facility, independent of the electrical grid when required. The aggressive construction schedule will continue over the next several months with focus on interior mechanicals, installation of cleanroom suites and manufacturing equipment, and building finishes. “The need for highly skilled production of DNA and RNA medicines is rapidly expanding,” stated VGXI President and CEO Mr. Young Park. “With this new purpose-built facility our company is perfectly positioned to leverage decades of expertise and robust, scalable DNA manufacturing technologies to meet these demands for both current and future clients.” The new VGXI headquarters offers multiple independent manufacturing suites with increased fermentation capacities up to the 1500L scale. Orders are now being taken for production slots starting in April 2022. BE&K Building Group is the design-builder of record, in partnership with architectural partner Hanbury and engineering partner Hipp Engineering & Consulting.

    ABOUT VGXI, INC. 

    VGXI, Inc., with 20 years of experience, is a leading provider of plasmid DNA manufacturing and development services. The company has a reputation of success in manufacturing DNA products under cGMP conditions for clinical trials in the US, EU, Asia, Canada, and Australia, and its cGMP and non-GMP products have passed rigorous reviews by several international regulatory agencies. VGXI’s ability to work with unique requirements and create custom manufacturing solutions is based on its patented manufacturing process, flexible cGMP production facility, and experienced development team. VGXI, Inc. is a GeneOne company.

    ABOUT GENEONE LIFE SCIENCE GeneOne Life Science Inc. (“GeneOne” KOSPI: 011000) headquartered in Seoul, South Korea is an international biotechnology company and a leading contract manufacturer of DNA plasmids for use in vaccines, gene therapies, and cell therapies. GeneOne has recently expanded into the manufacture and development of mRNA. GeneOne has maintained a focus on vaccines against emerging infectious diseases to address global needs, including in resource challenged regions. Its small molecule portfolio of immunomodulators address diseases such as prevention of upper respiratory bacterial and viral diseases, and treatment of autoimmune and inflammatory diseases. GeneOne has three products against COVID-19 in clinical development: GLS-5310 DNA vaccine (Phase I/IIa), GLS-1200 nasal spray to prevent COVID-19 infection (Phase II), and GLS-1027 to prevent the inflammation and clinical worsening for those infected with COVID-19 (Phase II). VGXI, Inc., a GeneOne company located in The Woodlands, Texas, is the global leading CDMO for cGMP DNA plasmid manufacture. For more information, visit http://www.genels.com.

    ABOUT BE&K BUILDING GROUP BE&K Building Group is an integrated construction services company serving pharmaceutical + biotechnology, advanced manufacturing + distribution, healthcare, and additional select commercial markets for more than 50 years. The company provides services nationwide through its operations in Houston, Chicago, and the Carolinas. A full range of services is offered including design-build, construction management, preconstruction, and client advisory/consulting. Additional information is available at https://bekbg.com.

    CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS Materials in this press release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. These statements can be identified by the fact that they do not relate strictly to historical or current facts. They include words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be incorrect. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of GeneOne stock. It is also important to read the disclosure notice contained in many of the individual GeneOne documents available on the website, as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports. Click here to view the official release on PRWeb. Media Contacts: Christy Franco, Ph.D. Sr. Manager, Business Development Click Here to Contact

  • Texas-based CDMO VGXI, Inc. is excited to announce that its partner, The Institute for Molecular Medicine, has recently been awarded a $12 million NIA grant to support clinical testing of a novel DNA vaccine manufactured by VGXI for the prevention of Alzheimer’s Disease.

    The Woodlands, TX – VGXI, Inc., an industry-recognized contract developer and manufacturing organization (CDMO) for nucleic acid biopharmaceuticals including DNA vaccines and gene therapies, announced that its partner, The Institute for Molecular Medicine (IMM), was recently awarded a $12 million grant from the U.S. National Institute on Aging (NIA) division of the U.S. National Institutes of Health (NIH) to support the clinical trial of IMM’s beta-amyloid (Aβ) targeted vaccine for the prevention of Alzheimer's Disease (AD). VGXI has been selected by IMM as its exclusive GMP plasmid manufacturing partner supporting clinical supply for IMM’s DNA vaccine, AV-1959D. IMM is a non-profit organization as well as their incubated spinoff Nuravax dedicated to developing safe and effective MultiTEP-based vaccines against neurodegenerative disorders including Alzheimer's disease. According to the Alzheimer’s Association annual report, in 2022, an estimated 6.5 million individuals over age 65 in the US are living with Alzheimer’s dementia, and more than 47 million people may have asymptomatic preclinical Alzheimer's disease. VGXI initially partnered with IMM in 2018 by providing the first GMP production batch for AV-1959D. The DNA vaccine is designed to induce an immune response against Aβ, and has demonstrated potential to inhibit Aβ aggregation and significantly delay disease progression in pre-clinical studies. An additional clinical production run for AV-1959D is currently in progress at VGXI’s Texas-based facility, and the therapy is set to enter Phase 1 clinical trials in the U.S. in Q2 2022. “VGXI is honored to continue supporting IMM and their collaborators with quality GMP plasmid manufacturing services,” stated VGXI CEO Young Park. “We look forward to enabling the successful first-in-man clinical trials for IMM’s preventive Alzheimer’s disease vaccine AV-1959D.” Dr. Michael Agadjanyan, Vice President of IMM and Head of the Department of Immunology stated, “In this double blind multicenter Phase 1 trial we will study safety and immunogenicity of AV-1959D vaccine in early AD subjects”. Read the full IMM press release regarding the NIH grant award here.

    ABOUT VGXI, INC. VGXI, Inc., with 20 years of experience, is a leading provider of plasmid DNA manufacturing and development services. The company has a reputation of success in manufacturing DNA products under cGMP conditions for clinical trials in the US, EU, Asia, Canada, and Australia, and its cGMP and non-GMP products have passed rigorous reviews by several international regulatory agencies. VGXI’s ability to work with unique requirements and create custom manufacturing solutions is based on its patented manufacturing process, flexible cGMP production facility, and experienced development team. VGXI, Inc. is a GeneOne company.

    ABOUT GENEONE LIFE SCIENCE GeneOne Life Science Inc. (“GeneOne” KOSPI: 011000) headquartered in Seoul, South Korea is an international biotechnology company and a leading contract manufacturer of DNA plasmids for use in vaccines, gene therapies, and cell therapies. GeneOne has recently expanded into the manufacture and development of mRNA. GeneOne has maintained a focus on vaccines against emerging infectious diseases to address global needs, including in resource challenged regions. Its small molecule portfolio of immunomodulators address diseases such as prevention of upper respiratory bacterial and viral diseases, and treatment of autoimmune and inflammatory diseases. GeneOne has three products against COVID-19 in clinical development: GLS-5310 DNA vaccine (Phase I/IIa), GLS-1200 nasal spray to prevent COVID-19 infection (Phase II), and GLS-1027 to prevent the inflammation and clinical worsening for those infected with COVID-19 (Phase II). VGXI, Inc., a GeneOne company located in The Woodlands, Texas, is the global leading CDMO for cGMP DNA plasmid manufacture. For more information, visit http://www.genels.com.

    ABOUT IMM The Institute for Molecular Medicine (IMM) is a non-profit organization created with the goal of understanding, preventing and curing chronic human diseases, including neurodegenerative disorders. Based in Orange County, California, IMM along with Nuravax, a biotechnology company licensed IMM's patented technology, is advancing MultiTEP, a universal vaccine platform technology that supports the development of multiple vaccine designs based on DNA, RNA or recombinant proteins.

    CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS Materials in this press release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. These statements can be identified by the fact that they do not relate strictly to historical or current facts. They include words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be incorrect. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of GeneOne stock. It is also important to read the disclosure notice contained in many of the individual GeneOne documents available on the website, as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

    Click here to view the official release on PRWeb.

    Media Contacts: Christy Franco, Ph.D. Sr. Manager, Business Development Click Here to Contact VGXI

  • VGXI Sign at the New Manufacturing Facility and Corporate Headquarters

    VGXI opened the doors of its new headquarters and manufacturing facility on 09Apr22 to provide friends and employee families a first look inside and outside the new site! As production is nearing completion, the event was an opportunity for employees and their families to tour the production suites, labs, and office spaces before the official grand opening event.

    Check out some additional insider images here: https://dsi.us/showcase/vgxi-project-dolphin/

    VGXI New Manufacturing Facility


 Products

  • GMP Plasmid Manufacturing
    VGXI's GMP plasmid manufacturing service has a proven track record of providing the highest quality DNA products for human clinical use....

  • VGXI has demonstrated capability to produce GMP plasmids at scales from a few hundred milligrams to over 40 grams or more per lot. Production suites include fermentor capacity from 10L to 1500L. Plasmid sizes produced range from < 3kb to about 19kb. VGXI can provide customized solutions for a client's challenging plasmids.